Gilead Sciences, Inc.
About Gilead Sciences, Inc.
Gilead Sciences is a biopharmaceutical company that discovers, develops, and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.
2247 articles about Gilead Sciences, Inc.
-
7 Top Companies Hiring Regulatory Jobs
3/14/2024
Looking for regulatory jobs in the biopharma industry? Check out the BioSpace list of seven top companies hiring for these critical roles. -
Gilead Sciences Announces Expiration of Hart-Scott-Rodino Waiting Period for CymaBay Tender Offer
3/11/2024
Gilead Sciences, Inc. announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 with respect to Gilead’s cash tender offer for CymaBay Therapeutics, Inc. expired at 11:59 p.m. on March 8, 2024.
-
Gilead Sciences Aids in Reducing Cancer Care Disparities: Dale Shares Her Breast Cancer Journey and the Power of Information Sharing
3/7/2024
For many people living with cancer, hearing about the experiences of others can be helpful.
-
Gilead Sciences is partnering with Dutch biotech Merus to find novel dual tumor-associated antigens that target tri-specific antibodies.
-
Biktarvy® Demonstrates High Rates of Viral Suppression in People With HIV and Comorbidities
3/6/2024
Gilead Sciences, Inc. announced new data from three studies evaluating the efficacy and safety profile of Biktarvy® for a broad range of people with HIV, including those with HIV/hepatitis B coinfection and HIV/tuberculosis coinfection.
-
Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24
3/6/2024
Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from the Phase 2 clinical study evaluating the investigational combination of islatravir, an investigational nucleoside reverse transcriptase translocation inhibitor, and lenacapavir, a first-in-class capsid inhibitor.
-
Gilead and Merus Announce Collaboration to Discover Novel Antibody-Based Trispecific T-Cell Engagers
3/6/2024
Gilead Sciences, Inc. (Nasdaq:GILD) and Merus N.V. (Nasdaq:MRUS) today announced a research collaboration, option and license agreement to discover novel dual tumor-associated antigens (TAA) targeting trispecific antibodies.
-
Gilead Sciences CEO on Company's Evolution and Commitment to the Bay Area
3/5/2024
Today the Foster City-based company is the second-largest biotech employer in the Bay Area.
-
New Real-World Data Further Support the Use of Veklury® (Remdesivir) for People Hospitalized With COVID-19
3/5/2024
Gilead Sciences, Inc. announced new data from three real-world retrospective studies being presented at the 31st Conference on Retroviruses and Opportunistic Infections.
-
Gilead’s Innovative HIV Treatment Research Pipeline Aims to Address Unmet Needs and Advance Public Health
3/5/2024
Gilead Sciences, Inc. announced the presentation of key data highlighting the breadth of its innovative HIV treatment research pipeline.
-
Retaining the full rights to Trodelvy, Gilead now has access to $210 million in financing from venture capital firm Abingworth to help push the antibody-drug conjugate into non-small cell lung cancer studies.
-
Gilead Announces Funding Initiative to Support HIV Prevention, Anti-Stigma and Health Equity Efforts for Black Cisgender and Transgender Women and Girls in the U.S.
2/27/2024
Gilead Sciences, Inc. announced it is providing a total of $12.6 million in grant funding to 19 organizations working to improve the HIV landscape for Black women and girls in the United States.
-
Gilead to Present Late-Breaking Data and Real-World Evidence Highlighting Innovative Antiviral Portfolio and Research Pipeline at CROI 2024
2/26/2024
Gilead Sciences, Inc. today announced the upcoming presentation of new clinical data and real-world evidence (RWE) from its antiviral research and development programs at the 31st Conference on Retroviruses and Opportunistic Infections (CROI 2024) taking place from March 3-6.
-
U.S. FDA Approves Expanded Indication for Gilead’s Biktarvy® to Treat People with HIV with Suppressed Viral Loads, Pre-existing Resistance
2/26/2024
Gilead Sciences, Inc. (Nasdaq: GILD) today announced the U.S. Food and Drug Administration (FDA) approved a new, expanded indication for Biktarvy® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) to treat people with HIV (PWH) who have suppressed viral loads with known or suspected M184V/I resistance, a common form of treatment resistance.
-
After a slow start to 2023 in an uncertain economic climate, biopharma mergers and acquisitions are on the rise.
-
Biocytogen and Gilead Enter Into a Multi-Target Antibody Collaboration Agreement
2/20/2024
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) today announces an antibody evaluation and option agreement with Gilead Sciences, Inc.
-
Gilead Sciences to Present at Upcoming March 2024 Investor Conferences
2/20/2024
Gilead Sciences, Inc. announced that its executives will be speaking at the following investor conferences.
-
While Gilead Sciences did not provide specific reasons for the halt, the company said it is “reviewing the benefit-risk” of its anti-CD47 antibody magrolimab across all ongoing trials.
-
Dragonfly Announces Clinical Collaboration Exploring Combinations of Dragonfly's DF1001 HER-2 TriNKET® with Gilead's Trodelvy® in two Cancer Indications
2/15/2024
Dragonfly Therapeutics, Inc. announced a new clinical collaboration designed to evaluate and combine DF1001, a HER-2 immune engager developed using Dragonfly's TriNKET technology platform and Dragonfly's lead clinical asset, with Trodelvy, Gilead's Trop-2-directed antibody drug conjugate, in metastatic breast cancer and non-small cell lung cancer.
-
Gilead Sets Sights on Hepatitis C Elimination As It Marks 10 Years of Curative Therapies
2/13/2024
Long-time liver specialist Carrie Frenette says she won't ever forget the people she treated for hepatitis C (HCV) before 2013 - the year that the Food and Drug Administration (FDA) approved a Gilead medicine.